NCT03110848View on ClinicalTrials.gov

Effects of Atorvastatin in Graves' Orbitopathy (GO)

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

April 30, 2021

Conditions
Thyroid Associated OphthalmopathyHypercholesterolemia
Interventions
DRUG

Atorvastatin

Atorvastatin 20 mg daily

DRUG

Methylprednisolone

500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.

Trial Locations (1)

56124

Ospedale Cisanello-Endocrinology I and II, Pisa

All Listed Sponsors
lead

University of Pisa

OTHER

NCT03110848 - Effects of Atorvastatin in Graves' Orbitopathy (GO) | Biotech Hunter | Biotech Hunter